Look up one drug

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more

1. Indications Therapy with lipid-altering agents should be considered a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to dyslipidemia. APO-PRAVASTATIN (pravastatin sodium) should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other non- pharmacological measures alone has been inadequate. Hypercholesterolemia • APO-PRAVASTATIN is indicated as an adjunct to diet (at least an equivalent of the Adult Treatment Panel III [ATP III TLC diet]) for the reduction of elevated Total and Low Density Lipoprotein Cholesterol (LDL-C) levels in patients with primary hypercholesterolemia (Types IIa and IIb), when the response to diet and other non-pharmacologic measures alone has been inadequate. • Prior to initiating therapy with APO-PRAVASTATIN, secondary causes for hypercholesterolemia, such as obesity, poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy or alcoholism, should be excluded and it should be determined that patients for whom trea… https://pdf.hres.ca/dpd_pm/00081202.PDF PM date: not printed or not captured Source product: APO-PRAVASTATIN; DIN 02243506; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.